Stock Market Reviews

RVPH (Reviva Pharmaceuticals Holdings, Inc.) News

Get the latest news, insights, and market updates on RVPH (Reviva Pharmaceuticals Holdings, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Reviva Pharmaceuticals Holdings (RVPH) Records 37% Gain So far in 2026
  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is one of the stocks under $1 that will explode. As of the market open on January 9, 2026, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has surged roughly 37% in 2026 so far, showcasing a strong share price momentum. However, at the same time, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is facing […]
  Jan 12, 2026 - $RVPH
• Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
  Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in a Phase 3 trial of brilaroxazine Findings also support use of speech latency as an enrichment tool that can reduce sample-size and enhance outcomes in clinical trials for schizophrenia CUPERTINO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage
  Jan 8, 2026 - $RVPH
• Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
  CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Sachs 9th Annual Neuroscience Innovation Forum, taking place January 11, 2026,
  Dec 29, 2025 - $RVPH
• Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
  Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of schizophrenia Current data package highlights long-term safety profile, broad-spectrum clinical activity, and favorable adherence observed to date for once daily brilaroxazine over up to one year Initiation of RECOVER-2 registrational trial planned in H1 2026, subject to sufficient finan
  Dec 23, 2025 - $RVPH
• RVPH: Brilaroxazine Poster Presentations
  By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported 3Q:25 results, confirming the pre-new drug application (NDA) meeting with the FDA in 4Q:25 to see if an NDA can be accepted using existing data. It reiterated the possibility of an NDA submission to the FDA in 2Q:26 if the agency indicates the application is
  Nov 24, 2025 - $RVPH
• Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
  – Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European patent granted covering use of brilaroxazine for the treatment of pulmonary fibrosis adds to existing patent protection in key global markets – CUPERTINO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmace
  Nov 13, 2025 - $RVPH
• Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025
  CUPERTINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that the anti-inflammatory impacts of brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the
  Nov 12, 2025 - $RVPH
• Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
  - Patent covers brilaroxazine use for treating Pulmonary Fibrosis -Similar patents have also been granted in key markets around the world including the United States, China, and Japan -Brilaroxazine has a novel mechanism of action for treating the underlying disruption in serotonin signaling implicated in the pathogenesis of Pulmonary Fibrosis CUPERTINO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharma
  Nov 10, 2025 - $RVPH
• Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference
  CUPERTINO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in Spartan Capital Securities Second Annual Investor Conference on November
  Oct 29, 2025 - $RVPH
• Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
  CUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that negative symptom data for brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the long-t
  Oct 28, 2025 - $RVPH